tradingkey.logo
搜尋

Nexalin Technology Inc

NXL
添加自選
0.361USD
-0.019-5.00%
收盤 07/02, 16:00美東報價延遲15分鐘
7.43M總市值
虧損本益比TTM

關於 Nexalin Technology Inc 公司

Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It has also designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.

Nexalin Technology Inc簡介

公司代碼NXL
公司名稱Nexalin Technology Inc
上市日期Sep 16, 2022
CEOWhite (Mark)
員工數量6
證券類型Ordinary Share
年結日Sep 16
公司地址1776 Yorktown
城市HOUSTON
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編77056
電話18322600222
網址https://nexalin.com
公司代碼NXL
上市日期Sep 16, 2022
CEOWhite (Mark)

Nexalin Technology Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Ms. Marilyn Elson
Ms. Marilyn Elson
Controller
Controller
1.21M
-27.03%
Mr. Mark White
Mr. Mark White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
309.13K
--
Dr. David Owens, M.D.
Dr. David Owens, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
192.25K
+3.38%
Mr. Alan Kazden
Mr. Alan Kazden
Independent Director
Independent Director
119.59K
+30.49%
Ms. Leslie Bernhard
Ms. Leslie Bernhard
Independent Chairman of the Board
Independent Chairman of the Board
49.84K
--
Ms. Carolyn Hamby Shelton
Ms. Carolyn Hamby Shelton
Senior Vice President - Quality, Regulatory and Clinical Affairs
Senior Vice President - Quality, Regulatory and Clinical Affairs
30.00K
--
Dr. Ben V. Hu, M.D.
Dr. Ben V. Hu, M.D.
Independent Director
Independent Director
--
--
Mr. Justin Van Fleet
Mr. Justin Van Fleet
Chief Financial Officer
Chief Financial Officer
--
--
名稱
名稱/職務
職務
持股
持股變動
Ms. Marilyn Elson
Ms. Marilyn Elson
Controller
Controller
1.21M
-27.03%
Mr. Mark White
Mr. Mark White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
309.13K
--
Dr. David Owens, M.D.
Dr. David Owens, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
192.25K
+3.38%
Mr. Alan Kazden
Mr. Alan Kazden
Independent Director
Independent Director
119.59K
+30.49%
Ms. Leslie Bernhard
Ms. Leslie Bernhard
Independent Chairman of the Board
Independent Chairman of the Board
49.84K
--
Ms. Carolyn Hamby Shelton
Ms. Carolyn Hamby Shelton
Senior Vice President - Quality, Regulatory and Clinical Affairs
Senior Vice President - Quality, Regulatory and Clinical Affairs
30.00K
--

常見問題

Nexalin Technology Inc的前五大股東是誰?

Nexalin Technology Inc的前五大股東如下:Ms. Marilyn Elson

有多少機構持有Nexalin Technology Inc(NXL)的股份?

截至2026Q1,共有43家機構持有Nexalin Technology Inc的股份,合計持有的股份價值約為1.43M,占公司總股份的6.94% 。與2025Q4相比,機構持股有所增加,增幅為524945.00。

哪個業務部門對Nexalin Technology Inc的收入貢獻最大?

在2026Q1,Device Sales業務部門對Nexalin Technology Inc的收入貢獻最大,創收136.00K,占總收入的45.09% 。